© 2005 European Society for Medical Oncology
Outpatient management in patients with neutropenia after intensive chemotherapyis it safe?
Department of Medicine, University Hospital, Freiburg, Germany
* (; Email: kern@medizin.ukl.uni-freiburg.de)
| The first 10% of the full text of this article appears below. |
Bone marrow involvement and intensive chemotherapy for remission induction and post-remission consolidation render the patient with acute leukemia (AL) highly vulnerable to fever and infection. Often, neutropenia lasts 3 weeks or longer, and the risk of developing fever approaches 100%. Patients with allogeneic and autologous bone marrow or peripheral blood stem cell transplantation (alloPBSCT and autoPBSCT) today often have shorter periods of neutropenia. In autoPBSCT patients, for
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Naithani, R. Kumar, M. Mahapatra, N. Agrawal, and P. Mishra Early discharge from hospital after consolidation chemotherapy in acute myeloid leukemia in remission: febrile neutropenic episodes and their outcome in a resource poor setting Haematologica, September 1, 2008; 93(9): 1416 - 1418. [Full Text] [PDF] |
||||
